Management of radiation maculopathy

Ophthalmic Research

Volumn 48, Issue SUPPL. 1, 2012, Pages 26-31

  Singh, Arun D ^a   Pabon, Sheila ^a   Aronow, Mary E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aflibercept; Bevacizumab; Maculopathy; Radiation; Ranibizumab

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; DEXAMETHASONE; EYLEAR; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ARTICLE; BRACHYTHERAPY; CHOROID MELANOMA; CLINICAL FEATURE; DIABETES MELLITUS; DRUG MEGADOSE; HEAD AND NECK CANCER; HUMAN; LASER COAGULATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTON RADIATION; RADIATION DOSE; RADIATION INJURY; RADIATION MACULOPATHY; RETINA MACULA EDEMA; RETINA MACULOPATHY; TELETHERAPY; UVEA MELANOMA;

ANGIOGENESIS INHIBITORS; BRACHYTHERAPY; CHOROID NEOPLASMS; FLUORESCEIN ANGIOGRAPHY; HUMANS; INCIDENCE; IODINE RADIOISOTOPES; LASER COAGULATION; MELANOMA; PHOTOCHEMOTHERAPY; RADIATION DOSAGE; RADIATION INJURIES; RETINA; RETINAL NEOVASCULARIZATION; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865401605     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000339844     Document Type: Article

References (32)

1. Archer DB, Amoaku WM, Gardiner TA: Radiation retinopathy-clinical, histopathological, ultrastructural and experimental correlations. Eye (Lond) 1991; 5: 239-251.
2. Monroe AT, Bhandare N, Morris CG, Mendenhall WM: Preventing radiation retinopathy with hyperfractionation. Int J Radiat Oncol Biol Phys 2005; 61: 856-864. (Pubitemid 40247982)
3. Irvine AR, Wood IS: Radiation retinopathy as an experimental model for ischemic proliferative retinopathy and rubeosis iridis. Am J Ophthalmol 1987; 103: 790-797. (Pubitemid 17082143)
4. Midena E, Segato T, Valenti M, Degli Angeli C, Bertoja E, Piermarocchi S: The effect of external eye irradiation on choroidal circulation. Ophthalmology 1996; 103: 1651-1660. (Pubitemid 26357143)
5. Horgan N, Shields CL, Mashayekhi A, Shields JA: Classification and treatment of radiation maculopathy. Curr Opin Ophthalmol 2010; 21: 233-238.
6. Stack R, Elder M, Abdelaal A, Hidajat R, Clemett R: New Zealand experience of I125 brachytherapy for choroidal melanoma. Clin Experiment Ophthalmol 2005; 33: 490-494. (Pubitemid 44056405)
7. Jensen AW, Petersen IA, Kline RW, Stafford SL, Schomberg PJ, Robertson DM: Radiation complications and tumor control after 125I plaque brachytherapy for ocular melanoma. Int J Radiat Oncol Biol Phys 2005; 63: 101-108. (Pubitemid 41583547)
8. Krohn J, Monge OR, Skorpen TN, Mork SJ, Dahl O: Posterior uveal melanoma treated with I-125 brachytherapy or primary enucleation. Eye (Lond) 2008; 22: 1398-1403.
9. Taban M, Taban M, Bolling J, Singh AD: Ocular complications of radiotherapy; in Singh AD, Damato BE, Pe'er J, Murphree AL, Perry JD (eds): Clinical Ophthalmic Oncology. Philadelphia, Saunders-Elsevier, 2007, pp 45-49.
10. Servodidio CA, Abramson DH: Acute and long-term effects of radiation therapy to the eye in children. Cancer Nurs 1993; 16: 371-381. (Pubitemid 23321725)
11. Gragoudas ES, Li W, Lane AM, Munzenrider J, Egan KM: Risk factors for radiation maculopathy and papillopathy after intraocular irradiation. Ophthalmology 1999; 106: 1571-1577; discussion 1577-1578.
12. Gunduz K, Shields CL, Shields JA, Cater J, Freire JE, Brady LW: Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999; 117: 609-614. (Pubitemid 29218426)
13. Melia BM, Abramson DH, Albert DM, et al: Collaborative Ocular Melanoma Study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology 2001; 108: 348-366. (Pubitemid 32115968)
14. Kinyoun JL, Zamber RW, Lawrence BS, Barlow WE, Arnold AM: Photocoagulation treatment for clinically significant radiation macular oedema. Br J Ophthalmol 1995; 79: 144-149.
15. Hykin PG, Shields CL, Shields JA, Arevalo JF: The efficacy of focal laser therapy in radiation-induced macular edema. Ophthalmology 1998; 105: 1425-1429. (Pubitemid 28509760)
16. Finger PT, Kurli M: Laser photocoagulation for radiation retinopathy after ophthalmic plaque radiation therapy. Br J Ophthalmol 2005; 89: 730-738. (Pubitemid 40780582)
17. Amoaku WM, Archer DB: Fluorescein angiographic features, natural course and treatment of radiation retinopathy. Eye (Lond) 1990; 4: 657-667.
18. Khan N, Khan MK, Bena J, Macklis R, Singh AD: Plaque brachytherapy for uveal melanoma: a vision prognostication model. Int J Radiat Oncol Biol Phys 2012, E-pub ahead of print.
19. Jones R, Gore E, Mieler W, et al: Posttreatment visual acuity in patients treated with episcleral plaque therapy for choroidal melanomas: dose and dose rate effects. Int J Radiat Oncol Biol Phys 2002; 52: 989-995. (Pubitemid 34219018)
20. Marwaha G, Wilkinson A, Bena J, Macklis R, Singh AD: Dosimetric benefit of a new ophthalmic radiation plaque. Int J Radiat Oncol Biol Phys 2012, E-pub ahead of print.
21. Oliver SC, Leu MY, DeMarco JJ, Chow PE, Lee SP, McCannel TA: Attenuation of iodine 125 radiation with vitreous substitutes in the treatment of uveal melanoma. Arch Ophthalmol 2010; 128: 888-893.
22. Horgan N, Shields CL, Mashayekhi A, et al: Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Ophthalmology 2009; 116: 1383-1390.
23. Bakri SJ, Beer PM: Photodynamic therapy for maculopathy due to radiation retinopathy. Eye (Lond) 2005; 19: 795-799. (Pubitemid 41030579)
24. Solano JM, Bakri SJ, Pulido JS: Regression of radiation-induced macular edema after systemic bevacizumab. Can J Ophthalmol 2007; 42: 748-749. (Pubitemid 350157568)
25. Finger PT: Anti-VEGF bevacizumab (Avastin) for radiation optic neuropathy. Am J Ophthalmol 2007; 143: 335-338. (Pubitemid 46136144)
26. Finger PT: Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiat Oncol Biol Phys 2008; 70: 974-977. (Pubitemid 351296131)
27. Gupta A, Muecke JS: Treatment of radiation maculopathy with intravitreal injection of bevacizumab (Avastin). Retina 2008; 28: 964-968.
28. Mason JO 3rd, Albert MA Jr, Persaud TO, Vail RS: Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina 2007; 27: 903-907. (Pubitemid 47479385)
29. Finger PT, Mukkamala SK: Intravitreal anti-VEGF bevacizumab (Avastin) for external beam related radiation retinopathy. Eur J Ophthalmol 2011; 21: 446-451.
30. Finger PT, Chin KJ: Intravitreous ranibizumab (Lucentis) for radiation maculopathy. Arch Ophthalmol 2010; 128: 249-252.
31. Querques G, Prascina F, Iaculli C, Delle Noci N: Intravitreal pegaptanib sodium (Macugen) for radiation retinopathy following episcleral plaque radiotherapy. Acta Ophthalmol 2008; 86: 700-701.
32. Finger PT, Chin K: Anti-vascular endothelial growth factor bevacizumab (Avastin) for radiation retinopathy. Arch Ophthalmol 2007; 125: 751-756. (Pubitemid 46919735)